摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

达赛马嗪 | 518-61-6

中文名称
达赛马嗪
中文别名
达西马嗪
英文名称
10-(N,N-dimethyl-glycyl)-10H-phenothiazine
英文别名
10-(N,N-dimethyl-glycyl)-phenothiazine;10-(N,N-Dimethyl-glycyl)-phenothiazin;10-[(dimethylamino)acetyl]-10H-phenothiazine;10-(N,N-dimethylglycyl)phenothiazine;dacemazine;2-(dimethylamino)-1-phenothiazin-10-ylethanone
达赛马嗪化学式
CAS
518-61-6
化学式
C16H16N2OS
mdl
——
分子量
284.382
InChiKey
HKUCYAHWPVLPFN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    144-145°
  • 沸点:
    484.9±34.0 °C(Predicted)
  • 密度:
    1.1641 (rough estimate)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    48.8
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934300000

SDS

SDS:4426b746626cb3e72e7630a25d977b88
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,10-二碘癸烷达赛马嗪乙醇 为溶剂, 反应 23.0h, 生成 N,N,N',N'-tetramethyl-N,N'-bis-(2-oxo-2-phenothiazin-10-yl-ethyl)-N,N'-decane-1,10-diyl-bis-ammonium; diiodide
    参考文献:
    名称:
    Braeuniger,H.; Mengering,S., Pharmazie, 1960, vol. 15, p. 600 - 603
    摘要:
    DOI:
  • 作为产物:
    描述:
    吩噻嗪 作用下, 生成 达赛马嗪
    参考文献:
    名称:
    Dahlbom; Ekstrand, Acta Chemica Scandinavica (1947), 1951, vol. 5, p. 102,104
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
    申请人:Johansen Lisa M.
    公开号:US20100009970A1
    公开(公告)日:2010-01-14
    The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
    本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中,病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中,病毒性疾病是病毒性肝炎(例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎),药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
  • Technology for the Preparation of Microparticles
    申请人:Malakhov Michael
    公开号:US20090098207A1
    公开(公告)日:2009-04-16
    Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触,并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
  • Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
    申请人:Scaramuzzino, Giovanni
    公开号:EP1336602A1
    公开(公告)日:2003-08-20
    New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.
    通式(I)的新药物化合物:F-(X)q,其中q是1到5的整数,最好是1;-F是在文本中描述的药物中选择的,-X是在文本中描述的4个组-M,-T,-V和-Y中选择的。通式(I)的化合物是硝酸盐前药,可以在体内以受控和选择性的方式释放一氧化氮,而不会产生降压副作用,因此它们非常适用于制备用于预防和治疗肌肉骨骼,皮肤,呼吸,消化,泌尿和中枢神经系统的炎症,缺血,退行性和增生性疾病的药物。
  • Compositions and methods to effect the release profile in the transdermal administration of active agents
    申请人:——
    公开号:US20020004065A1
    公开(公告)日:2002-01-10
    Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.
    本发明涉及一种用于经皮递送活性药剂的组合物和方法,该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂,包括一种药学上可接受的粘合基质和一种聚合物塑料材料,该聚合物塑料材料对活性药剂具有释放速率调节作用。
  • Diagnostic/therapeutic agents
    申请人:Klaveness Jo
    公开号:US20050002865A1
    公开(公告)日:2005-01-06
    Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.
    可定位的诊断和/或治疗活性剂,例如超声对比剂,包括悬浮在水载体液中的报告物,该报告物包含含气体或生成气体的材料,该剂能够与目标形成至少两种结合对。
查看更多